Opioid-related neurocognitive symptoms among patients on long-term opioid therapy were most prevalent during the course of therapy.

Distribution of prescribed opioid analgesics is lower in majority non-White versus majority White communities across all levels of socioeconomic deprivation.

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

It is expensive, with a list price of $15.50 per pill. But unlike opioid pain medicines, it cannot become addictive. That is because the drug, suzetrigine, made by Vertex Pharmaceuticals and to be ...

The oral drug, branded Journavx, works by blocking pain signals at their source, unlike opioids — which trigger the brain's reward centers as they travel through the blood and then attach to ...

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and ...

Journavx (suzetrigine), a non-opioid pill for moderate-to-severe acute pain, has just received FDA approval. It’s the first drug in a new family of medicines that block pain signals before they ...

Copyright 2025 The Associated Press. All Rights Reserved. U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The US Food and ...

The FDA has approved Vertex Pharmaceuticals’ Journavx, a new pain medication designed to reduce the risk of addiction and overdose associated with opioids. Intended for short-term pain after surgeries ...